Curanex Pharmaceuticals financials
$5.08+0.90%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$3.3M | -$3.2M | -$3.1M | -$951.3K |
| Net income | -$3.3M | -$3.2M | -$3.1M | -$954.1K |
| Net margin | — | — | — | — |
| Diluted EPS | $-2.40 | $-2.20 | $-2.16 | $-0.80 |
| EBITDA | -$3.3M | -$3.2M | -$3.1M | -$951.3K |
| Operating cash flow | -$1.1M | -$954.6K | -$857.4K | -$9.2M |
| Free cash flow | -$1.1M | -$954.6K | -$857.4K | -$9.2M |
| Diluted shares | 1.4M | 1.4M | 1.4M | 1.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 |
|---|---|---|---|---|
| Cash & equivalents | $2.9M | $4.0M | $5.0M | $5.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.1M | $8.4M | $11.6M | $14.5M |
| Total liabilities | $286.3K | $332.6K | $361.0K | $186.0K |
| Shareholders' equity | $4.8M | $8.1M | $11.2M | $14.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology